BiotechTube
ProThera Biologics

ProThera Biologics

Providence, United States· Est.
protherabiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ProThera Biologics, founded in 2001, is developing first-in-class biologic therapies based on Inter-alpha Inhibitor Proteins (IAIP) to treat severe inflammatory conditions with high unmet need. The company's platform leverages a multi-pathway anti-inflammatory mechanism, targeting complex diseases like severe community-acquired pneumonia, stroke, and neonatal hypoxic-ischemic brain injury. As a private, likely pre-revenue entity, ProThera is advancing both therapeutic and diagnostic (biomarker) applications of IAIP, positioning itself in a challenging but high-potential segment of the immunology market.

Severe Inflammatory DiseasesPneumoniaStrokeNeonatal Brain InjuryNeonatal Sepsis

Technology Platform

Inter-alpha Inhibitor Proteins (IAIP) – a class of human plasma proteins that broadly modulate multiple inflammatory pathways and promote tissue repair, used as both a replacement therapy and a diagnostic biomarker.

Opportunities

The high unmet need in severe inflammatory conditions (pneumonia, stroke, neonatal injury) allows for potential premium pricing and orphan drug benefits.
The multi-pathway mechanism of IAIP offers a differentiated approach in a market where single-target anti-inflammatories have often failed in critical care.
The dual therapeutic/diagnostic strategy for neonatal sepsis could create a synergistic product offering.

Risk Factors

High clinical development risk associated with a novel, complex biologic in acutely ill patients.
Significant financial risk as a pre-revenue company needing substantial capital for trials.
Competitive risk from large pharma and other biotechs targeting inflammation, though with different mechanisms.

Competitive Landscape

ProThera operates in the crowded anti-inflammatory space but with a unique, multi-target mechanism. It faces indirect competition from cytokine inhibitors (e.g., anti-IL-6) being tested in critical care, and from neuroprotective agents in stroke. In neonatal HIE, its primary competitor is therapeutic hypothermia, the current standard of care. Its broad-pathway approach is its key differentiator.

More companies in Biologics / Biosimilars →More companies in United States →